The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last ...

AstraZeneca announced plans for $2 billion in new spending on research and development, bringing its total capital investment ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

Eric Le Berrigaud has given his Buy rating due to a combination of factors that reflect AstraZeneca’s strong performance and future potential. The company demonstrated robust growth in the third ...

Before I hand over to AstraZeneca, I’d like to read the Safe Harbor statement. The company intends to utilize the Safe Harbor ...

AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second ...

UK-based biopharmaceutical company AstraZeneca has announced a $3.5bn investment to expand its research and manufacturing ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

AstraZeneca PLC (NASDAQ:AZN) reported a 21% increase in total revenue for Q3, driven by strong global demand for its ...

Shares in AstraZeneca were down 1.3 percent in midday deals on London's top-tier FTSE 100 index, which was trading one ...